ABSTRACT
INTRODUCTION
Although methadone is the only substitution medication recommended for treating pregnant opiate-dependent women, a large number of French women are treated with buprenorphine, which has been registered in France for maintenance therapy since 1996. A few data have been published concerning buprenorphine exposure during pregnancy. Most of the studies are retrospective (Table 1) or include neonates at birth; they assess the neonatal abstinence syndrome. The prospective follow-up of pregnant treated women concerns only a small number of women (Table 2) .
With the support of the French Programme Hospitalier de Recherche Clinique , we are currently conducting a multi-centre observational prospective study comparing the effects of buprenorphine and methadone in two groups of pregnant women. At present, the comparative study is not complete. However, due to the increasing number of inclusions in the buprenorphine group compared with the methadone group, we think that the publication of preliminary results for the buprenorphine group could help the profession in the decision to use a drug that does not have a medical license for use in pregnant women. I. Lacroix et al.
Thus, we report results of 34 prospective pregnancy follow-ups after buprenorphine intake for maintenance therapy for opiate dependence during pregnancy.
METHODS
The pregnant women were recruited from opiate maintenance therapy centres, general practitioner networks involved in addiction, maternity hospitals and centres of drug information in pregnancy. All pregnant women receiving a registered maintenance therapy were included as early as possible during their pregnancy and before the eighth month of pregnancy.
For each woman, the following data were collected: socio-demographic data, medical and gynaecological history, duration of addiction, use of illicit drug, alcohol and tobacco, all prescribed and self-medication drugs and obstetrical events. For all drugs, period of exposure, dosage, route of administration and indication were recorded. Results of urinary tests were also recorded. In order to obtain complete and accurate information, the investigator interviewed the gynaecologist, the general practitioner and the psychiatrist. Each month after inclusion (more frequently when unexpected events occurred), Table 1 Retrospective studies on buprenorphine in pregnancy.
Reference
Number of exposed women Pregnancy outcome Marquet et al . (1997) 1 Mild withdrawal syndrome Regini et al . (1998) 1 Severe withdrawal syndrome Fischer et al . (1998) Table 2 Prospective studies on buprenorphine in pregnancy.

Number of exposed women Pregnancy outcome
Reisinger 1997 4 4 normal birth outcomes 1 restlessness in a child at day 13 Jernite et al . (1999) 11 1 premature baby, 1 in utero retardation 7 withdrawal syndromes Auriacombe et al . (1999) 4 3 births 3 withdrawal syndromes Fischer et al . (2000) 15 15 healthy babies 7 withdrawal syndromes Johnson et al . (2001) 3 3 normal birth outcomes 3 withdrawal syndromes data concerning drug and medication use, medical and obstetric events and results of antenatal follow-up were recorded during a medical consultation. After delivery the investigator met each woman in the hospital, collected further data about drug, alcohol and tobacco consumption and interviewed her about medical events that could have occurred before delivery. Concerning offspring, the following parameters were recorded by a paediatrician: birth weight, characteristics and severity of withdrawal syndrome, malformations, neonatal diseases and neonatal mortality. The intensity of the withdrawal syndrome was assessed six times per day by the paediatrician or the paediatric nurse using the score of Finnegan (Finnegan, Connaughton & Kron 1975) (range: 0-39). For each baby, 1 month after birth, the investigator phoned the physician taking care of the child in order to obtain information about its health status.
RESULTS
Thirty-four buprenorphine-exposed women were included at 142 ± 11 days of pregnancy. The women were recruited from two opiate maintenance therapy centres ( n = 11), two maternity hospitals ( n = 13) and from general practitioners ( n = 10).
Socio-demographic data, gynaecological history, viral status, drug, alcohol and tobacco use are presented in Table 3 . The gynaecological history of the women was heavy: the mean numbers of voluntary terminations, miscarriages and therapeutic abortions were, respectively, 1.0 ± 1.4 (0-7), 0.5 ± 0.8 (0-4) and 0.1 ± 0.5 (0-3).
Pregnancy follow-up
All the women were exposed to buprenorphine since the beginning of pregnancy (the treatment had been prescribed before). Only one woman suspended the treatment herself at the 12th week of pregnancy because she was afraid that the medication could be dangerous for her fetus. Figure 1 shows the doses used according to the pregnancy period. The mean dose of buprenorphine was 6.6 ± 4.9 mg/day (from 0.4 to 32 mg/day) during early pregnancy and 3.9 ± 4.6 mg/day (from 0.1 to 32 mg/ day) at the end of pregnancy. These doses are similar to those reported by Loustauneau et al . (2002) in a recent review. The decrease in buprenorphine dosage at the end of pregnancy can be explained by the wish of the mothers and the medical team to prevent neonatal withdrawal syndrome. A lower dosage at the end of pregnancy was also observed by Fischer et al . who described a similar rate of withdrawal syndrome.
According to the results of the urinary assays before delivery, eight women (23.5%) had a positive result for cannabis during late pregnancy; six (17.6%) for benzodiazepines and two (5.9%) for heroine. Moreover, 22 (64.7%) said that they smoked and three (8.8%) that they are alcohol abusers (Table 3) . Medication consumption during pregnancy is presented in Table 4 . Associateddrug consumption was also reported by Lejeune et al . (2001) , who did not find any difference for this parameter between buprenorphine and methadone consumers.
Ten patients experienced a medical event during pregnancy: metrorrhagia ( n = 2), excess of amniotic fluid ( n = 1), arterial hypertension ( n = 1), cervix uteri dysplasia ( n = 1) and threat of premature labour ( n = 5).
Pregnancy outcomes
The length of gestation was 38.4 ± 2.5 weeks. The buprenorphine-exposed pregnancies ended in 31 live births, one stillbirth, one spontaneous abortion and one voluntary termination. Three newborns (9.7%) were delivered before 35 weeks of pregnancy.
It is difficult to compare these results to already published data because the number of prospective follow-ups is low and retrospective studies include only births (abortions and fetal deaths are not recorded).
The case of stillbirth concerns the woman who stopped buprenorphine at the 12th week of pregnancy. It was her first pregnancy following in vitro fertilization. The woman occasionally consumed heroin and smoked 10 cigarettes per day. The fetal death occurred at the 23rd week of pregnancy after gravidic toxaemia. No malformation or chromosomal anomaly was identified in the fetus. However, visceral necrosis lesions were observed.
The occurrence of a withdrawal syndrome or successive intake and stoppage of drugs during pregnancy could be associated with fetal suffering and even fetal death (Umans & Szeto 1985) .
Newborn
The newborns had a birth weight of 2796 ± 558 g (1240-3920 g) and a length of 47.4 ± 2.1 cm (44-52). These results are similar to those observed in newborns who were exposed in utero to methadone (Fraser 1976; Brown, Britton & Mahaffey 1998) . Kandall et al . (1976) described a higher birth weight for methadone-exposed neonates than heroin-or heroin + methadone-exposed babies. Our results are close to the data of Lejeune et al . (2001) , who included neonates whose mothers had been treated by buprenorphine during pregnancy. Consumption of opiates as well as of other drugs (nicotine, alcohol . . . ), precariousness of life-style and poor prenatal follow-up are involved in the decrease of gestation length, birth weight and size when compared to the general population.
Concerning the six neonates from HIV + mothers, mean weight was 3167 ± 529 g and mean size 49 ± 2 cm. One child had a minor malformation (tragus appendice). His mother had been treated by lamivudine and zidovudine. Another woman had been treated by the same association, one by zidovudine and nalfinavir, two by lamivudine, zidovudine and nevirapine and one by lamivudine, zidovudine and indinavir.
Malformations
One baby had a premature ductus arteriosus stricture leading to a pericardial effusion and a heart murmur. Its mother was suffering from an antiphospholipid syndrom treated by aspirin (160 mg daily). She also consumed cannabis. Non-steroid anti-inflammatory drugs have been shown to increase the risk of premature closure of the ductus arteriosus (Momma & Takeuchi 1983) . Another neonate had a tragus appendix. He was exposed in utero to buprenorphine, sulfamethoxazole, trimethoprime, lamivudine and zidovudine. No data on the occurrence of such minor malformations after drug exposure could be found.
Withdrawal syndrome
Neonatal withdrawal syndrome, assessed using the Finnegan neonatal abstinence scoring system, was observed in 13 cases (41.9%) (score > 5) and eight of these babies required opiate treatment. The mean value for maximal Finnegan score was 11.0 ± 3.6 (from 5 to 16). Neonatal abstinence signs occurred between 1 and 8 days after birth (mean value: 3.0 ± 2.6 days). Nine of the 13 babies suffering from neonatal abstinence syndrome were exposed in utero to other psychoactive drugs: withdrawal syndrome occurred for three babies from six mothers taking benzodiazepines during late pregnancy, for one baby from two mothers exposed to illicit opiates, for five babies from eight mothers consuming cannabis and for 10 babies from 22 consuming nicotine.
The observed rate of neonatal withdrawal (42%) seems to be lower than for neonates exposed to methadone (50-90%) (Fraser 1976; Dawe, Gerada & Straug 1992; Lejeune et al . 2001) or heroin (79-92%) (Brown, Britton & Mahaffey 1998; Giles et al . 1989) . It is in accordance with the results of Fischer et al . (2000) but lower than the mean rate of neonatal syndrome computed by Loustauneau et al . (2002) in a recent review of the literature (65%) and observed by Lejeune et al . (2001) using the Lipsitz score (65%). Figure 2 shows the occurrence of a withdrawal syndrome according to buprenorphine dosage in late pregnancy. The mean dosage of buprenorphine was 2.9 ± 2.5 mg for babies with a withdrawal syndrome and 4.6 ± 6.8 mg for the others. Two cases of severe withdrawal syndrome (Finnegan scores reaching 11 and 14) were associated with maternal cannabis consumption.
CONCLUSION
Pregnancy in opiate abusers can lead to various complications for the mother as well as the fetus and neonate. Maintenance therapy of drug-addicted mothers with psychosocial support may reduce these adverse events. In 1996, buprenorphine was registered in France for the treatment of opiate dependence. Conversely to methadone, which is prescribed and delivered in specialized care centres, all French general practitioners are allowed to prescribe sublingual tablets of buprenorphine and the medication can be obtained in every French pharmacy. This regulation enables easy access to a maintenance treatment. Thus, in 2001, 74 000 subjects were undergoing buprenorphine treatment in France and an increasing number of pregnant French women are exposed to buprenorphine (OFDT 2002) .
The present prospective study which includes buprenorphine-exposed patients as early as possible in their pregnancy gives preliminary information not only on the neonatal withdrawal syndrome but also on pregnancy follow-up and outcome. Taken together with other prospective reports (Reisinger 1997; Johnson et al . 2001) or studies (Fischer et al . 2000) , no alarming results have been observed at the present state of the survey concerning pregnancy outcomes or neonatal withdrawal frequency and severity. Thus, at the present time, there seems to be no reason to change from buprenorphine to methadone when the woman was taking buprenorphine during the first weeks of her pregnancy. Such a change can, potentially, expose the patient to several complications (difficulty to find the equipotent dose, risk of withdrawal syndromes during the switch, risk of losing touch with the patient). However, further data from the comparative prospective study are required to determine whether buprenorphine actually is a good alternative to methadone treatment in pregnant women. 
